Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The members of the picornavirus family include various viruses which, due to their impressive oncolytic activity, have the potential to be used for the treatment of cancer. However, the replication of these oncolytic viruses (OV) is not limited to tumor cells but can also take place in various normal tissues. To increase the safety of these OV, target sites (miR-TS) of microRNAs, which are expressed in normal tissues but are absent or only expressed at low levels in cancer cells, can be inserted into the viral genome. Here we describe how miR-TS can easily be inserted into the complementary DNA (cDNA) of coxsackievirus B3 (CVB3) RNA genome using the In-Fusion cloning technology. Here we provide the step-by-step protocol, how miR-TS containing recombinant CVB3 can be generated from these viral cDNA constructs, how the virus is amplified, purified and concentrated, and how the functionality of the miR-TS within the viral genome can be confirmed.

Original publication

DOI

10.1007/978-1-0716-2441-8_14

Type

Journal article

Journal

Methods Mol Biol

Publication Date

2022

Volume

2521

Pages

259 - 282

Keywords

Coxsackievirus B3, In-Fusion cloning, Oncolytic virus, Virus plaque purification, cDNA, microRNA target sites, microRNAs, DNA, Complementary, Enterovirus B, Human, Genome, Viral, HeLa Cells, Humans, MicroRNAs, Oncolytic Viruses, Virus Replication